The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial
Open accessAbstract
BACKGROUND According to international treatment guidelines, inhaled rapid-acting β2 agonists should be used for the control of symptoms in patients with asthma. We compared the efficacy and safety of an extrafine combination inhaler containing a corticosteroid (beclometasone) plus a rapid-onset, long-acting β2 agonist (formoterol) with a short-acting β2 agonist (salbutamol) as reliever strategies in patients taking beclometasone-formoterol combination as maintenance treatment. METHODS In a double-blind trial undertaken in 183 centres in 14 European countries over 48 weeks, patients (aged ≥18 years) with asthma that was not fully controlled, with a forced expiratory volume in 1 s (FEV1) of at least 60% predicted, had a 2-week run in. During this period, patients were treated with a combination of beclometasone 100 μg and formoterol 6 μg per one inhalation twice daily plus salbutamol 100 μg as required delivered by use of a pressurised metered-dose inhaler. They were then randomly assigned in a 1:1 ratio with a computer-generated randomisation list to receive beclometasone 100 μg plus formoterol 6 μg or salbutamol 100 μg as reliever in addition to maintenance with beclometasone 100 μg plus formoterol 6 μg twice daily. Primary outcome was the time to first severe exacerbation (admission to hospital or visit to emergency department, or use of systemic steroids for ≥3 consecutive days). Secondary outcomes were number of severe exacerbations (events per 100 patients per year), time to and number of mild exacerbations, additional exacerbation variables, lung function, symptom scores, and asthma control. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT00861926. FINDINGS 1714 patients were randomly assigned to the as-needed beclometasone-formoterol (n=857) and as-needed salbutamol groups (n=857), and 1701 were analysed (852 and 849, respectively). 326 severe exacerbations were reported by 251 patients during the study, and 99 versus 152 patients had at least one exacerbation during the 48 weeks, respectively. Compared with beclometasone-formoterol plus salbutamol as needed, beclometasone-formoterol for both maintenance and reliever treatment significantly increased the time to first exacerbation (209 days vs 134 days) by 75 days, with a 36% reduction in risk (hazard ratio 0·64 [95% CI 0·49 to 0·82]; p=0·0005), and the estimated probability was 12% and 18%, respectively (p=0·0003). The number of days with mild asthma exacerbations was also lower with as-needed beclometasone-formoterol than with as-needed salbutamol (56·04 days per patient per year vs 65·11 days per patient per year; 0·86 [0·76 to 0·98]; p=0·021). From the run-in period to week 48, both treatments improved symptoms (mean change -1·59 [-1·94 to -1·25] in the as-needed beclometasone-formoterol group vs -1·44 [-1·78 to -1·10] in the as-needed salbutamol group, difference -0·15 [-0·60 to 0·30]; p=0·507), percentage of asthma control days (9·5% [7·3 to 11·8] vs 10·9% [8·7 to 13·1], respectively, -1·4 [-4·3 to 1·6]; p=0·359), use of reliever (-0·29 [-0·38 to -0·20] vs -0·27 [-0·36 to -0·19], respectively, -0·02 [-0·13 to 0·10]; p=0·794), and lung function (FEV1, 0·090 [0·060 to 0·120] vs 0·090 [0·060-0·120], respectively, 0·001 [-0·040 to 0·040]; p=0·969), and were well tolerated (patients with serious adverse events, 32 [4%] and 41 [5%], respectively). INTERPRETATION Our results lend support to the use of the combination of a single inhaled corticosteroid plus a rapid-onset, long-acting β2 agonist for maintenance and relief in patients with moderate to severe asthma and provide encouraging data for the formulation of beclometasone-formoterol for this use. FUNDING Chiesi Farmaceutici.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma
O'Byrne, P. M., Bisgaard, H., Godard, P. P., Pistolesi, M., Palmqvist, M., Zhu, Y., Ekström, T., & Bateman, E. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-884oc · Cited by 657
Haselkorn, T., Chen, H., Miller, D. P., Fish, J. E., Peters, S. P., Weiss, S. T., & Jones, C. A. (2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.04.006 · Cited by 65
Cited by
Papi, A., Brightling, C., Pedersen, S. E., & Reddel, H. K. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33311-1 · Cited by 1,759
Self-citationCloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.10.003 · Cited by 854
A summary of the new GINA strategy: a roadmap to asthma control
Reddel, H. K., Bateman, E. D., Becker, A., Boulet, L.-P., Cruz, A. A., Drazen, J. M., Haahtela, T., Hurd, S. S., Inoue, H., de Jongste, J. C., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00853-2015 · Cited by 788
Holgate, S. T., Wenzel, S., Postma, D. S., Weiss, S. T., Renz, H., & Sly, P. D. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.25 · Cited by 652
Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma
O’Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715274 · Cited by 645
Metadata
- Authors
- Papi, A., Corradi, M., Pigeon-Francisco, C., Baronio, R., Siergiejko, Z., Petruzzelli, S., Fabbri, L. M., & Rabe, K. F.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 1
- Issue
- 1
- Pages
- 23-31
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2156543153
- Cited by
- 170
- References
- 2
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-2600(13)70012-2
- The paper
- Papi, A., Corradi, M., Pigeon-Francisco, C., Baronio, R., Siergiejko, Z., Petruzzelli, S., Fabbri, L. M., & Rabe, K. F. (2013). Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(13)70012-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.